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Disclaimer 
These Guidelines are based, in most cases, on the reports drawn up by the chairs of the disease-based workshops run by EMQN and the CMGS. These workshops 
are generally convened to address specific technical or interpretative problems identified by the QA scheme. In many cases, the authors have gone to considerable 
trouble to collate useful data and references to supplement their reports. However, the Guidelines are not, and were never intended to be, a complete primer or 
"how-to" guide for molecular genetic diagnosis of these disorders. The information provided on these pages is intended for chapter authors, QA committee members 
and other interested persons. All the guidelines are at a draft stage, and must not be used until formally published. Neither the Editor, the European Molecular 
Genetics Quality Network, the Clinical Molecular Genetics Society, the UK Molecular Genetics EQA Steering Committee nor the British Society for Human Genetics 
assumes any responsibility for the accuracy of, or for errors or omissions in, these Guidelines. 
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NOMENCLATURE AND GENE ID 
See table 1 
 
Locus FRAXA Gene FMR-1 
OMIM# 309550 GeneCard Fragile-X 
 
 
DESCRIPTION OF THE DISEASE 
The fragile X syndrome (a.k.a. Martin-Bell Syndrome) is the most common cause of inherited mental retardation 
with an estimated incidence of 1 in 4000-9000 males 1 and 1 in 7000-15000 females. In affected boys, delay in 
language acquisition and/or behavioural problems are often the presenting symptoms. In addition to cognitive 
deficits, the phenotype of fragile X syndrome includes mild dysmorphic features (large everted ears, coarse facies, 
elongated face) and macroorchidism established around puberty. Behavioural disturbances including attention-
deficit hyperactivity or autistic-like behaviour can be observed.  
 
Females can also be affected. Approximately 50-60% of female carriers of the disease causing mutation will have 
mild to moderate mental retardation.  
 
THE GENE AND THE MUTATIONS 
The gene involved (termed FMR1 for Fragile X mental retardation), located in Xq27.3,  encodes an RNA-binding 
protein (FMRP) 2,3,4. FMRP has been shown to bind with high affinity to RNA structures called G quartets, and lists 
of candidate mRNA targets for FMRP action were defined. Proteins interacting with FMRP have been identified, 
two of which provide a link with the Rho/Rac signalling pathway implicated in other forms of X linked mental 
retardation 5,6,7,8. 
 
Fragile X syndrome is caused in most of cases by expansions of a (CGG) trinucleotide repeat in the 5’UTR of the 
FMR1 gene, and subsequent abnormal methylation of neighbouring CpG island leading to the loss of the protein 
product FMRP (Figure 1). 
 
 
Figure 1: 
Figure 1 : Scheme of normal and expanded alleles at the FMR1 locus. On the top is the map of the DNA fragment 
that contains the CGG repeat at the 5 ’ end of FMR1 gene green box). The CpG region corresponds to a regulatory region that
becomes abnormally methylated in the full mutation. 
On the left the genotype- phenotype correlation is indicated, with the pattern of transmission of expanded alleles.
Empty symbols  normal allele, no mental retardation. Symbol with central dot : premutation carrier, with no mental retardation.
Filled black symbol : full mutation carrier with mental retardation, filled grey symbol : full mutation carrier with mental retardation 
in 50-60% of the cases.
CpG island
FMR1 gene
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The normal form of the CGG repeat is polymorphic and contains from 6 to about 50 trinucleotide repeats, in 
general interspersed with 1-3 AGG triplets 3, 9, 10  with 29-30 repeats being the most common alleles. 
 
Alleles in the 59-200 CGG repeat range without abnormal methylation are referred to as premutations.  
Premutations do not cause mental retardation but were shown to be associated with premature ovarian failure in 
females and late onset tremor/ataxia syndrome in males 11,12. Some recent studies report the occurrence of an 
autistic disorder in patients with fragile X premutation, but this association deserves further study to estimate its 
prevalence 13,14,15. Premutations are unstable and, when transmitted by a female, have a risk of expanding to a full 
mutation. This risk of transition is very strongly dependent on the size of the maternal premutation, and is above 
95% for alleles with more than 100 repeats 16,17. The smallest described allele that underwent transition to a full 
mutation in a single generation is 59 CGG repeats without AGG interruption 18. 
 
Alleles with CGG repeats in the intermediate range between normal and premutation (50 to 58 repeats) can show 
some  instability upon paternal and maternal transmission. It is thought that 'pure' CGG repeats are less stable than 
repeats with interspersed AGG sequences 19. The results from several epidemiological studies suggest that alleles 
above 52+/-1 CGG  have a prevalence around 1 in 100 females in the general population (reviewed in 20). 
 
The disease-causing full mutation is a large expansion exceeding 200 repeats, and is usually accompanied by 
methylation of the adjacent promotor region 21 which results in transcriptional silencing of FMR1. Indeed, it appears 
that fragile X syndrome is due to absence of functional FMRP as deletions and point mutations in the FMR1 coding 
sequence have also been reported to cause the syndrome 22,23,24,25. These events are rare. A hot spot for deletions 
that occurred in the context of an expanded allele, has been identified in FMR1 exon 1 26,27.  
 Full mutations are unstable not only during transmission but also within fragile X patients. This somatic instability 
leads to two types of size mosaicism. (1) There is the wide range of repeat lengths of the full mutation. (2) Some 
rare  fragile X patients are mosaic for a full mutation and an allele in normal range (or full mutation, premutation 
and normal range). 
 
The term "Fragile X syndrome" is commonly used to refer to the syndrome caused by CGG expansions and other 
FMR1 mutations. However, in a small number of families, another fragile site has been  linked to expansions at the 
nearby FRAXE locus of the FMR2 gene. FMR2 contains an unstable (CCG)n repeat whose expansions are 
responsible for a milder phenotype of nonsyndromic mental impairment 28,29,30,31.  
 
REASONS FOR REFERRAL 
Reasons for referral are diffuse and include a wide range of mental impairment from  profound mental retardation 
to mild learning difficulties, as well as developmental delay, autistic-like behaviours, hyperactivity and other 
behavioural problems.. 
 
Carrier detection and prenatal diagnosis are other reasons for referral. 
Another indication is the occurrence of premature ovarian failure (POF) in a female, especially in cases of familial 
premature ovarian failure. Based on studies reviewed by S.L. Sherman 11, approximately 20% of female 
premutation carriers have POF compared to only 1% in the general population.  
 
A possible indication is presenile tremor/ataxia (termed FXTAS) which might turn out to be associated with the 
fragile X premutation, particularly in males, but more studies are still warranted to establish its prevalence . 
 
APPROACHES 
The diagnostic procedure is mainly based on Southern blotting (DNA digested with specific restriction 
endonucleases) or on direct amplification of the CGG-repeat using flanking primers. Alternative 
immunocytochemical tests have been described.  
 
Southern blotting allows the identification of all expansions as well as the determination of the methylation status. 
Using standard PCR amplification, alleles above 120 CGGs are difficult to detect although more efficient  
techniques  are being developed. Accurate sizing of premutations requires the use of PCR. This is crucial to 
assess the risk of carrier females having affected children, and to distinguish intermediate alleles from 
premutations. 
 
Attention is drawn in these guidelines to  the potential  for misinterpretation due to the specific pitfalls of each 
method, and to the technical limitation of each protocol. A statement of these limitations should appear clearly in 
the conclusion section of the molecular diagnosis report.  
 
Southern blot analysis 
This test is based on the sizing of the CGG repeat by Southern blotting. Southern blot analysis using a single 
enzyme (EcoRI with StB12.3 or equivalent probes, see figure 2) allows the detection of full mutations and large 
premutations, and is sufficient for testing  of probands with learning difficulties. However, it is often combined with 
methylation analysis using a methylation-sensitive enzyme such as EagI or NruI which offers a very good strategy 
in family studies to detect premutations, full mutations and mosaic patterns 32.  
 When high quality Southern blots with appropriate controls are analysed, interpretation is straightforward . 
However, high background and weak signal can lead to misinterpretations and, particularly, smears of expanded 
fragments can be very faint and easily overlooked.  
 
The need for radioactive handling can be avoided since a non radioactive approach using a chemiluminescent 
probe  has been tested 33 and is currently used in several laboratories. High quality Southern blots were presented 
at the Strasbourg Best Practice Meeting by Wout Deleen (Rotterdam, The Netherlands), Christalena Sofocleous 
(Athens, Greece) and Paula Jorge (Porto, Portugal). 
 
Figure 2: 
EcoRI EcoRIPstI PstI PstIXhoI
1 kb
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Figure 2 : Probes used in the diagnosis of Fragile X syndrome (modified from Oostra et al.69)
Probe Ox1.9 and Ox0.55 can be obtained from Professor Kay Davies in Oxford. St probes are available from
Professor Jean -Louis Mandel in Strasbourg. Pfxa3 is available from the ATCC, with restrictions
 
 
 
 
PCR analysis 
Compared to Southern blotting, the PCR test is more rapid and easy to use but its approach encounters particular 
technical difficulties 34. Also, the primers should be checked carefully that they do not bind to a sequence where a 
SNP has been found. The amplification of large CG rich fragments is a laborious task and, since the first PCR test 
described by Fu et al.3, several methods have been published which detect alleles in the normal range and more or 
less in the premutation range (for example up to 200 repeats with Ethidium – visible detection 35, and up to 120 
repeats with automated capillary electrophoresis 36). As a consequence, many laboratories use PCR as a first test, 
and only proceed to Southern blot on samples which fail to amplify (males) or show a single normal allele 
(homozygous normal females representing around 20% of females).  
 An internal control is required to distinguish a non amplifiable allele with a probable expansion from an 
unsuccessful PCR reaction 37. PCR for FMR1 can usefully be duplexed with PCR for FMR2 29 which provides an 
internal control with a similar CGG repeat but this strategy should be discussed with local clinicians before use. 
Some primer positions are indicated in Table 4.  
 
One possible concern about using PCR for fragile X diagnosis is that affected males mosaic for normal and full 
mutations might be missed (MoMN individuals), as the PCR would only amplify the normal allele. In a study of 300 
males with a full mutation ascertained by Southern blot and, using primers from Fu et al. 1991 3, we have estimated 
that around 1% of full mutation males have a PCR amplifiable allele within the normal range. We have also 
detected a mosaic carrier female with 35 CGG, 50 CGG, premutated and full mutated alleles. Such cases would be 
diagnosed as normal using a PCR test. The possibility of size mosaics (normal/premutation or normal/full mutation) 
should  therefore be taken into account, especially when testing in known fragile X  families. 
 
A false positive case has also been reported and shown to be caused by a 5 bp deletion preventing primer 
annealing and leading to an apparent null allele while the CGG repeat was in the normal range 38. This underlines 
the need for complementing PCR analysis with Southern blotting. 
 
Nevertheless PCR tests have been described which should detect full mutated / normal allele mosaicism and are 
discussed below  30,39,40,41,42.  
 
Immunohistochemistry FMRP protein 
Test for the presence  or absence of the FMRP protein have been developed using immunohistochemistry 43. 
Validated postnatal applications include blood smears for males and hair roots for both sexes. Logistic 
considerations are the major reasons for not making widely use of the FMRP test in diagnostic laboratories. 
Application on blood smears requires either fresh ('same day') blood or needs to be made immediately  if the blood 
sample cannot be dispatched rapidly. Hair roots  tolerate handling by regular mail, but the test must be done within 
5 days after receipt of the sample. These tests are not  considered as a practical routine procedure in most 
laboratories. Thus the FMRP test is mainly used for large scale testing 44,45 and for the assessment of difficult 
cases (i.e. patients with suggestive clinical phenotype but no expansion) but it is of limited use in most diagnostic 
laboratories. The test has been reported in the study of some fetuses but it has not been fully validated on chorion 
villi or amniotic fluid cells due to limited availability of material 46,47,48,49. 
 
GENOTYPE 
Detecting full expansions and/or methylation status 
Using measurement of the CGG repeat, it may be difficult to distinguish a large premutation from a small full 
mutation. In such cases, determination of the methylation status is of great importance: premutations are not 
methylated while full mutations are usually methylated. However, fully expanded repeats that are completely or 
partially unmethylated have been reported in patients with a moderate or normal phenotype (“high-functioning” 
fragile X males) 50,51.  
 
Southern blot analysis 
The most commonly used enzymes are EcoRI and HindIII, which give normal fragments of approximately 5.2kb. 
Several equivalent probes are in use (see Figure 2). 
 
Expanded repeats are unstable upon transmission from parent to offspring and can, therefore,  show up as a 
diffuse smear rather than as a single enlarged band or a mixture of the two. If an expansion is suspected but the 
smear is too blurred to be sure about, digesting with BglII (which gives a normal fragment size of approximately 12 
kb) will compress the smear enough to make it easily detectable. A female with a faint smear may be used as a 
control. As the amount of DNA can vary, the intensity of bands has to be compared in order to know if the normal 
bands are strong enough to exclude a faint smear.  
 
A methylated full mutation (appearing as one or more sharp fragments) is usually stable somatically 52,53 but is 
never transmitted stable within the family. If this appears to be the case, incomplete digestion or a restriction site 
polymorphism which prevents the enzymatic digestion should be checked for 54. 
 
Tarleton et al 55 reported a point mutation within the CGG repeat which creates a new EagI restriction enzyme site 
and this appears as a deletion event.  
 
When the methylation status is to be determined, EcoRI is combined with a methylation-sensitive enzyme such as 
EagI or NruI, which gives a fragment of approximately 2.8 kb from the normal, unmethylated FMR1 gene. 
Methylated normal alleles are not cut by  methylation sensitive enzymes, and give rise to  the normal 5.2-kb EcoRI 
fragment. Methylated and unmethylated expansions are indicated by the presence of bands and/or smears above 
5.2 kb and 2.8 kb  respectively. In females, an X-inactivation bias  between the methylated and unmethylated 
normal fragments (skewed X-inactivation) is an  indication that an expansion may be present, but an inactivation 
bias is not always associated with an expansion. 
 
PCR analysis 
PCR tests specifically optimized to detect large expansion and/or methylation status have been described. One of 
them is a PCR test combined with Southern blot followed by chemiluminescent probe detection which resolves 
both normal, premutation and full mutation alleles 39. Some tests were specifically modified in order to detect large 
expansions and/or methylation status: they involve a methylation-sensitive restriction enzyme 30 or bisulphite 
treatment of DNA prior to amplification  40,41. Weinhaeusel et al. 42 have developed a methylation-sensitive 
polymerase chain reaction (MS-PCR) strategy that combines repeat-length and methylation analysis of the CGG-
repeat and the promoters of the FMR1 and XIST genes. The allelic methylation of the latter opposes that of the 
FMR promoter and serves as an internal control and standard for semiquantitative analyses. Nevertheless, the 
interpretation of this test may be tricky in a female with a full mutation due to the presence of  the methylated 
inactive normal X chromosome. A false-positive MS-PCR based diagnosis of fragile X syndrome has recently been 
reported to the assessors of the fragile X quality assessment scheme. 
 
The methyl-sensitive PCR techniques are not suitable for early prenatal diagnosis since the tests are based on 
DNA methylation which is not completed in chorionic villi samples and prenatal testing with DNA from 
amniocentesis has not been fully evaluated.  
 
Detecting premutations 
 
Southern blot analysis 
In the methylation sensitive digest, premutations are detected as fragments of 2.9 to about 3.3 kb  in males and on 
the active X chromosome in females, whereas the 5.3 to 5.7 kb fragments correspond to the premutation on the 
inactive X chromosome. Note that the FMR1 promotor is fully methylated on normal inactive X chromosomes in 
females. X-inactivation methylation of premutations should not be misinterpreted as an indication of the presence 
of a methylated full mutation. 
 
It should be noted that in some female carriers of a premutation, biased X inactivation (skewing) can result in an 
atypical banding pattern (2.8 kb + expansion and 5.2 kb or 2.8 kb and 5.2 kb + expansion). Great care should be 
taken to ensure that the 2.8 and 5.2 kb bands are clearly aligned with the neighbouring tracks to exclude this 
possibility. A control probe, StA22, associated with StB12.3, has been developed which allows a check on the 
homogeneity of migration throughout the gel 56. This probe is very useful in cases of a small premutation and/or a 
premutation with  skewed inactivation, and for the detection of migration artefacts ( e.g. with an inappropriate DNA 
extraction protocol, with samples extracted from blood in Lithium Heparin tubes, sample overloading, ….).  
 
Although most premutations can be detected in these conditions, it is often necessary to determine the size of 
small expansions more accurately. An alternative Southern blot test is possible with PstI digest (with StB12.3XX, 
Pfax3 or OX 0.55 probes 57) but the required increase in resolution could be more accurately achieved with CGG 
PCR. 
 
PCR analysis 
PCR analysis is very useful for accurate sizing under 120 CGGs, i.e. to discriminate between normal, grey zone 
and small premutation alleles. Only in the latter case, an estimation of the transition risk upon female transmission 
can be done 18. 
 
PRENATAL DIAGNOSIS  
For prenatal diagnosis, PCR and Southern blot approaches have the same sensibility, sensitivity, and pitfalls as 
were discussed above for lymphocyte  DNA analysis, with the exception that the use of a methylation sensitive 
method is not suitable on chorionic villi DNA because methylation of the full mutation is not always present at the 
8th-10th week of pregnancy 58. Also, in contrast to lymphocytes and amniocytes, the FMR1 gene is not methylated 
on the inactive X chromosome in the chorionic villi of female fetuses.   
 
A methylation sensitive analysis would lead to the division of a mutated signal into two classes, methylated and 
unmethylated fragments, which would be more difficult or impossible to detect. For this reason it is preferable to 
use only a methylation insensitive enzyme for prenatal Southern blots. 
 
In prenatal diagnosis, the size of the expansion is the most important consideration. In the case of a signal in the 
large premutation/small full mutation range, determination of the methylation status normally is critical for distinction 
between the two classes of mutations and an EagI+EcoRI digest  should be done on a DNA sample from amniotic 
fluid cells or fetal blood to give a definitive result. 
 
Since DNA amounts and concentrations available from prenatal samples may be low, it can be difficult to exclude a 
very heterogeneous mutation that appears as a very faint smear. It is important to load similar amounts of DNA in 
all lanes if possible, and it may be useful to include another probe specific for another locus to demonstrate the 
presence of sufficient fœtal DNA. In a female fœtus, a normal signal is always present. It can be useful to compare 
the intensity of this signal to the expected intensity in order to be as sure as possible that a weak signal is not 
missed. 
 
Note that indirect diagnosis with microsatellite markers is still of some value because of its  speed in a prenatal 
diagnosis context, especially when Southern blotting is not possible or had inconclusive results, or when not 
enough DNA is available. Then a result may be  rapidly obtained with a  normal (non-risk) haplotype. But a 
determination of the expansion size is necessary  when the at-risk haplotype is detected in the fœtus. Of course, 
samples from appropriate family members are essential to determine the  phase of the haplotype.  
 
Furthermore microsatellites are the recommended way to detect/exclude maternal contamination of the fetal DNA 
sample which can lead to a false diagnosis, especially with the CGG PCR technique. We have detected significant 
maternal contamination in 3 out of 206 prenatal diagnoses. Some microsatellites markers are given in Table 5. 
 
INTERPRETATION 
 
The following size ranges of CGG repeats and the corresponding interpretations were suggested at the Best 
Practice meeting in Strasbourg. 
 
Number of repeats Result 
<50 repeats Normal range 
50-58 repeats Intermediate Alleles = grey zone 
 
>58 – 200 repeats (not methylated on the active X ) Premutation  
>200 repeats (usually abnormally methylated on 
the active X ) 
Full mutation.  
Table 2   : Potential inaccuracy in sizing should be born in mind when interpreting the results based on this table. It 
is reasonable to accept a maximum error of +/- 4 % of the total repeat size. 
 
Normal range 
• Although minor changes in repeat numbers upon parental transmission have been described for alleles of 46-
49 repeats, these are judged to be of no significance for genetic counselling. 
 
Intermediate alleles = grey zone alleles 
• Possible instability upon transmission, but transition to a full mutation allele in one generation has never been 
reported  
• Because these alleles might display size instability upon transmission to offspring , referral to the local genetic 
counselling  service for further family studies is recommended to clarify this. 
• Prenatal diagnosis should be offered to women with 55 repeats and above. 
The Strasbourg Meeting did not consider it necessary to perform further analysis (e.g. of AGG interspersions), 
as there is not enough research data available to enable quantitative predictions about the stability of such 
alleles. However AGG interruptions are generally thought to stabilize  CGG arrays in this size range. 
 
Premutation 
• Unstable upon transmission. The risk for a female of having an affected child is proportional to the premutation 
size 18.  
• About 20% of females carrying a premutation have premature ovarian failure (before 40y of age). This is 
important in genetic counselling of young females. 
• Although a suspicion of FXTAS is an indication to search for a premutation, the prevalence of this late onset 
syndrome is not yet known and one should be cautious in  specifying a risk for a relative found with a 
premutation in  the context of carrier testing. 
• The interpretation of a newly detected premutation allele depends entirely upon the reason for referral.  
♦ In "query carrier" referrals in known fragile X families, a premutation in a female denotes that she is a 
carrier , with a risk of having affected children. The risk for a female premutation carrier of having affected 
children is proportional to the size of the premutation (but potential inaccuracy in sizing should be kept in 
mind).  
♦ In an asymptomatic male from a fragile X family, a premutation denotes a  "normal transmitting male" ; 
the premutation will be transmitted, with little or no change in size, to all his daughters, but will not expand to 
a full mutation in one generation. In a diagnostic query (patient with mental retardation) interpretation of a 
premutation is more difficult. There is the possibility of mosaicism, with full mutations being present in tissues 
other than blood, as premutations are not usually associated with mental retardation. Nevertheless, this 
finding has implications for the family, as other members may be at risk of  transmitting fragile X syndrome. It 
is recommended that at risk individuals are referred to the local Genetic Counselling service for further 
investigation.  
•  Confirmation of a prenatal result by amniocentesis could be offered in cases where a premutation  has been 
found in chorionic villi DNA, in order to detect or exclude somatic mosaicism. No discrepancy had been  
observed by the meeting group, but these cases are rare. 
 
Full mutation 
• Males with full mutations will develop  fragile X syndrome. Exceptions are extremely rare, and are likely to 
involve tissue or methylation mosaicism 50,51,59,60,61 
• Approximately 60% of females with full mutations are mentally retarded although their level of retardation is, on 
average, less severe than that seen in males. Many have some form of learning difficulty and behavioural 
problems. 
 
REPORTING 
 
Although local policy can vary with regard to reporting, some cases and suggested items to be included in the 
report are set out in Table 3. 
 
 Report 
 Genotype Interpretation 
Reason for 
referral 
 Diagnostic Carrier status 
 
• Report the presence of normal allele(s) 
Southern  MALE AND FEMALE 
• This sample had no 
expansion /  normal 
allele(s) 
• Report that the fragile X diagnosis is unlikely 
but not ruled out (possibility of point mutation or 
gene deletion) 
• Report that she/he is not a carrier of the 
fragile X syndrome caused by an expansion 
Southern 
+ 
MALE AND FEMALE 
• This sample had an 
 
• Report the presence of an allele in intermediate range 
 PCR allele in the 
intermediate range 
• Report that the fragile X  diagnosis is unlikely 
but not ruled out (possibility of point mutation or 
gene deletion) 
• MALE AND FEMALE : mention the indication 
of genetic counselling for the family 
• MALE AND FEMALE  : he/she is at risk  of 
being a carrier of fragile X syndrome  
• FEMALE : information about her risk of having 
affected children and about the possibility of 
prenatal diagnosis 
• MALE AND FEMALE : mention the indication 
of genetic counselling for the family  
 
• Report the presence of a premutation 
Southern 
(and PCR) 
MALE AND FEMALE  
• This sample had a 
premutation  • A premutation is usually not associated with 
mental retardation. Report that the fragile X 
diagnosis is unlikely but not ruled out 
(possibility of tissue mosaicism or point 
mutation or gene deletion) 
• he/she is a carrier of fragile X syndrome  
• FEMALE : information about her risk of having 
affected children and about the possibility of 
prenatal diagnosis (and about POF) 
• MALE AND FEMALE : mention the indication 
of genetic counselling for the family 
• he/she is a carrier of fragile X syndrome  
• FEMALE : information about her risk of having 
affected children and about the possibility of 
prenatal diagnosis (and about POF) 
• MALE AND FEMALE : mention the indication 
of genetic counselling for the family  
If appropriate, e.g. in cases of presenile 
tremor/ataxia and/or dementia, give information 
on FXTAS. 
 
• Report the presence of the full mutation 
Southern MALE AND FEMALE  
• This sample had a full 
mutation • Report that the fragile X  diagnosis is 
confirmed 
• FEMALE : she is a carrier of fragile X 
syndrome  
• FEMALE : information about her risk of having 
affected children and about the possibility of 
prenatal diagnosis 
• MALE AND FEMALE : mention the indication 
of genetic counselling for the family 
FEMALE  
• she is a carrier of fragile X syndrome  
• information about her risk of having affected 
children and about the possibility of prenatal 
diagnosis 
• mention the indication of genetic counselling 
for the family  
    
(PCR pre-
screening) 
 
 
MALE 
• This sample had a 
normal allele 
 
 
 
 
• This sample had no 
normal allele 
 
FEMALE 
• This sample had one 
normal allele 
• This normal allele is 
homozygous or 
hemizygous 
 
 
 
 
FEMALE 
• This sample had two 
 
• Report the presence of a normal allele 
• Report that the diagnosis of fragile X 
syndrome is unlikely but not ruled out 
(possibility of point mutation or gene deletion or 
CGG expansion mosaicism) 
 
No or preliminary report : Southern blot required
 
 
• Report the possibility of homozygosity for this 
normal allele or the presence of an expansion 
based on the sensibility of the test used 
• Note that complementary analysis has to be 
done to distinguish between  normal 
homozygous female or a female with an 
expansion. 
 
• Report the presence of two normal alleles 
• Report that the fragile X  diagnosis is unlikely 
but not ruled out (possibility of point mutation or 
gene deletion or CGG expansion mosaicism) 
 
Preliminary reports can be issued but  
confirmation by a method which is able to 
detect large premutations and full mutations 
also is required. 
 
normal alleles 
 
 
    
Table 3 : Items used as criteria for marking in the four fragile X External Quality Assessment schemes provided by 
EMQN since 2001. 
 
“Best Practice guidelines for “reporting” are available at the EMQN web site (www.emqn.org). The following points  should be 
included in each report: 
 
• Date of referral / arrival noted 
• Laboratory reference 
• No typographical errors 
• Individual reports issued 
• Reason for referral restated : clear distinction between diagnostic testing, carrier testing and prenatal diagnosis 
• Clear and concise report : “background” information about testing methodology, etc, be kept in the background 
• Testing method and approximate repeat numbers mentioned or error limits provided 
• Clear and concise conclusion, presented prominently 
• Report dated and signed by two suitably qualified persons 
 
TECHNICAL PROTOCOLS 
 
Size Markers/Control samples 
It is essential to include size markers in all types of Fragile X analysis. The most useful markers are those which lie 
at the borders between normal and intermediate allele and between premutation and between intermediate allele 
and premutation.  
 
A cell line has been established for one female with a premutation allele of 59 repeats established by sequencing 
and is available from the American Type Culture Collection. Other cell lines from the Coriell Cell repositories 
(Camdem, NJ) have been sequenced 62. 
 
For Southern blots it is useful to include a female with a small premutation on Southern - if the premutation is not 
distinguishable from the normal band, the gel has not run far enough. A useful marker will help to identify a partial 
digest which may well be mistaken for a mutated fragment 57. An alternative is to include a partial digest at least 
once (fragments resulting from an incomplete EcoRI digest have around 6.5; 9 and 10 kb and a 4.1 kb fragment 
appears also in EagI incomplete digestion with StB12.3). 
 
CGG PCR 
 
The primer sequences are taken from the references indicated. Individuals should consult the appropriate 
reference for full instructions and information on primer use.  
 
Reference Primer sequence Position locus Genbank 
Accession L29074 
Fu et al 3 
 
5’-GCTCAGCTCCGTTTCGGTTTCACTTCCGGT-3' 
5’-AGCCCCGCACTTCCACCACCAGCTCCTCCA-3’ 
13712-13723 
13992-13963 
 
 (CGG)n 13833-13892 
Wang et al 29 5’-TGACGGAGGCGCCGCTGCCAGGGGGCGTGC-3’ 
5’-GAGAGGTGGGCTGCGGGCGCTCGAGGCCCA-3’ 
13796-13825 
13923-13897 
 
 
Table 4 : Some primer references and positions. Note that there is a hot-spot of deletion of the CGG  with the 5’ 
breakpoint between position13748 and 13780 26  
 
 
Microsatellites Markers 
 
A table of useful markers is set out below. FRAXAC1 and FRAXAC2 show essentially zero recombination with the 
(CGG)n repeat. The high degree of linkage disequilibrium between FRAXAC1 and FRAXAC2 makes them less 
informative for indirect genotyping. DXS548, DXS297, and DXS8091 are widely used. Although less informative, 
DXS998 and DXS1215 are closest to the CGG repeat and may be of some interest. Although very rare, gene 
conversion, recombination events and reduction of full mutation to premutated or even normal allele have been 
described, and have to be considered in indirect diagnosis  32,63,64,65,66,67,68. The possibility of microsatellite instability  
or of a null allele (described for DXS548 by Vaisanen et al 66 and found in several  chromosomes in our lab, 
unpublished results) should be taken into consideration.  
 
 
Locus Het Fragment 
size 
 
DXS297 
(VK23) 
0.66 179-195 bp 5'-TTGGACTTCCCAAGCCTCCACAA-3'  
5-TTCTGAGTCTGTGCAGTGTATTTGTCAG-3' 
DXS998 0.57 113-119 bp 5’-CAGCAATTTTTCAAAGGC-3’ 
5’-AGATCATTCATATAACCTCAAAAGA-3’ 
DXS548 
(RS46) 
0.64 190-206 bp 5'-AGAGCTTCACTATGCAATGGAATC-3'  
5'-GTACATTAGAGTCACCTGTGGTGC-3' 
 
FRAXAC1 0.67 145-165 bp 5'-GATCTAATCAACATCTATAGACTTTATT-3'  
5'-GATGAGAGTCACTTGAAGCTGG-3' 
(CGG)n    
FRAXAC2 0.80 145-165 bp 5'-GACTGCTCCGGAAGTTGAATCCTCA-3'  
5'-CTAGGTGACAGAGTGAGATCCTGTC-3' 
DXS1215 0.55 242-250 bp 5’-GGGCAAAACATTAAACCTCTC-3’ 
5’-GCCCTCTAAGTCATTACGCT-3’ 
DXS8091 0.76 89-111 bp 5’-CACATTCAGGTTCCACAGG-3’ 
5’-CAAGATCCAGGCAAAAGTC-3’ 
Table 5 : Microsatellites 
 
 
INTERNET RESOURCES 
Department Clinical Genetics, Erasmus University Rotterdam, Pays-Bas (FMRP Test) 
http://www.eur.nl/FGG/CH1/fragx/  
 
FRAXA Research Foundation, USA   
http://www.fraxa.org/  
 
GeneClinics, University of Washington, Seattle, USA 
http://www.geneclinics.org  
 
The National Fragile X Foundation, San Francisco, USA 
http://www.nfxf.org  
 
Human Genome Epidemiology Network, USA   
http://www.cdc.gov/genetics/hugenet/reviews/FragileX.htm  
 
National Center for Biotechnology Information, USA   
http://www.ncbi.nlm.nih.gov/disease/FMR1.html  
 
National Library of Medicine, USA   
http://www.nlm.nih.gov:medlineplus:ency:article:001668.htm  
 
University of Western Ontario, London, Canada.   
http://www.icondata.com/health/pedbase/files/FRAGILEX.HTM  
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